Introduction
Gene therapy is a rapidly evolving field of medicine, which potentially offers new options for the treatment of cardiovascular diseases. Vascular endothelial growth factor (VEGF) is a mitogen for vascular endothelial cells, causing their proliferation and migration, which can improve endothelization. It is also a cytoprotective and anti-apoptotic factor leading to the inhibition of neointimal growth during vascular damage, and inducing angiogenesis especially in ischaemic tissues. [1] [2] [3] [4] [5] [6] [7] Therapeutic angiogenesis and inhibition of restenosis were the first targets of VEGF gene therapy. 2, 5, 7, 8 The VEGF family consists of several members: VEGF (also called VEGF-A), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental growth factor. They all act through specific tyrosine kinase receptors. [5] [6] [7] Current cardiovascular gene therapy trials have mostly been carried out using VEGF-A.
1,2,4,6-10 Potential long-term adverse effects of the increased VEGF gene expression could be related to excessive vascular growth in non-target tissues, such as the retina of diabetic patients and malignant tumours. Adenoviruses have shown their potential efficacy in vascular gene transfer. 2, 9, 11 As short-term side effects, they have caused transient inflammatory effects, such as short-term fever, elevation of C-reactive protein (CRP) and formation of anti-adenovirus antibodies. 2, 12, 13 Liposomes are safe, but their gene transfer efficiency is much lower when compared with that of adenoviruses. The therapeutic effect of non-viral gene transfer is long lasting compared with that of adenoviral gene transfer. 9, 7, 11, 13 In addition, they can also cause fever and moderate increases in CRP. It is also possible that elevated CRP and fever after non-viral gene transfer might also be related to the invasive procedure itself. 1, 2, 13, 14 Although the short-term safety of VEGF gene therapy has been excellent, there are very limited results regarding the long-term effects and safety of VEGF gene therapy. The first report of the Kuopio Angiogenesis Trial (KAT) examined the feasibility, efficiency and short-term safety of VEGF gene therapy with adenovirus and plasmid/liposome vectors, in patients undergoing elective coronary intervention (percutaneous coronary intervention, PCI). 2 The followup time was 6 months, when the patients were re-admitted to the hospital for analyses of safety and efficiency. The aim of this study was to explore the longterm effects and safety of VEGF gene therapy in patients with coronary artery disease (CAD).
Results
The mean follow-up time was 8.1 years (6.9-9.7 years). Eighty-nine (83%) patients answered either the telephone interview or the questionnaire. Baseline characteristics of the KAT patients are shown in Table 1 . No significant differences were found between the study groups at the baseline.
Safety follow-up
A total of eight patients (7.5%) had died during the follow-up. There were no significant differences in the mortality between the study groups (3/32 vs 2/26 vs 3/31 VEGF-adenovirus vs VEGF-plasmid/liposome vs placebo, respectively; P ¼ 0.88, Table 2 ). One patient died because of acute myocardial infarction, one patient because of a rupture of an aortic aneurysm, whereas in other patients, the reason for death was a malignant disease (two patients with a colon carcinoma with metastases, one with a rectum carcinoma with metastases, one with a malignant glioblastoma, one patient with an invasive basocellular nasal carcinoma and one patient with chronic leukaemia). Thus, a new cancer was diagnosed during the follow-up in seven (7%) patients, and one patient had two malignancies (Table 2) . A new onset of Type II diabetes was diagnosed in six (6%) patients. None of the patients with diabetes had developed either diabetic retinopathy or nephropathy.
Cardiac symptoms and major cardiovascular adverse effects (MACEs)
According to the patients' own opinion, 40 (44%) patients were free of symptoms. Correspondingly, exercise tolerance was impaired in 49 (56%) patients. The limiting symptom was angina pectoris in 10 (9%), dyspnoea in 20 (18%) and exhaustion in 13 (12%) patients (Table 3 ). The rest of the patients had some other reason for impaired exercise tolerance, such as chronic arthrosis and back pain. Most of the symptoms were graded as CCS (Canadian Cardiological Society) 2. Twenty-four (27%) patients were still working, 18 (20%) patients had retired because of CAD and 43 (49%) patients had retired for other than cardiac reasons. One patient was currently on a sick leave due to CAD, and two patients were on a sick leave because of other reasons. There were no significant differences between the study groups regarding cardiac symptoms, exercise tolerance or the ability to work.
Only two (2%) deaths related to the cardiovascular system were reported during the long-term follow-up. Thirteen (15%) patients had an acute coronary syndrome during the follow-up. Repeated coronary angiography was carried out in 21 (24%) patients. Eight (9%) patients were treated with PCI and seven (8%) patients had undergone a coronary by-pass operation (coronary artery bypass grafting, CABG). Two (2%) patients had a stroke. Major adverse cardiac events (MACEs), consisting of cardiac death, acute coronary syndrome, coronary intervention or stroke, were present in 36 (38%) patients ( Figure 1 ). No significant differences in MACE were found between the study groups. Eleven (13%) patients had been examined due to cardiac arrhythmias. A cardiac pacemaker was implanted in one patient (1%) due to symptomatic bradycardia.
Discussion
The KAT was the first randomized, blinded and placebocontrolled gene therapy trial, using catheter-based VEGF gene transfer in patients undergoing PCI. The short-term safety of vascular gene therapy either with adenoviruses or plasmid/liposomes was excellent. Plasmid/liposomes were also well tolerated. They caused transient fever and moderate increases in the CRP levels. 1, 2, 13, 14 In this study, we show that intracoronary VEGF gene transfer with adenovirus and plasmid/liposome vectors is safe and well tolerated.
Vascular endothelial growth factor gene transfer was used instead of recombinant protein administration, because gene transfer leads to a local production of therapeutic proteins for several days. [5] [6] [7] Vascular endothelial growth factor was chosen as a therapeutic agent, because of its vasculoprotective and angiogenic properties. Vascular endothelial growth factor gene therapy resulted in an increased myocardial perfusion in isotope perfusion scintigraphy. 2 As VEGF enhances neovascularization, there is a possibility for unwanted vessel growth in non-target tissues, such as in diabetic Long-term safety of VEGF gene therapy M Hedman et al retinopathy or in dormant tumours. In the first report of the KAT, intracoronary VEGF gene transfer did not increase the risk of malignant tumour growth or diabetic retinopathy after a 6-month follow-up, 2 nor did it increase the risk of malignancies after a 1.5-year followup. 13 These results are in line with other reports.
14, [16] [17] [18] [19] In the KAT, morbidity and mortality were rather low during the 8.1-year follow-up. This might be because of the fact that the patients were screened using very strict inclusion and exclusion criteria. The patients were relatively young and did not have other major diseases, such as diabetes, in addition to CAD. Furthermore, their CAD was local, because the patients with diffuse CAD were excluded from the trial. Only short coronary lesions optimal for PCI were included. This might explain the low number of acute coronary syndromes and repeated coronary interventions during the follow-up. Most of the patients reported that the treatment had improved their quality of life. Nevertheless, no differences were found between the gene therapy and the control groups with regard to coronary events, cardiac symptoms and MACE after the long-term follow-up. It is important to note that only one patient died due to myocardial infarction. Thus, it seems pertinent to conclude that gene therapy causing transient VEGF expression does not induce the progression of either atherosclerosis or CAD. 20 Even though malignant diseases had caused most of the chronic morbidities in patients participating in the trial, the incidence of cancer was not increased significantly in the VEGF groups. All malignancies were diagnosed more than 2 years after the gene transfer. Even though the incidence of malignancies tended to be higher in the plasmid/liposome group, the difference was not statistically significant. Furthermore, the incidence of cancer was not different from that reported in the general Finnish population (0.5-0.8 new cancers per 100 persons per year; Finnish Cancer Registry 2005, Finland).
In the first gene therapy trials, intracoronary or i.v. injections of therapeutic genes were used. Owing to this, several therapeutic angiogenesis trials have been carried out using intramyocardial VEGF gene transfer. 1, 8, 19 Preclinical studies in pigs have shown some pericardial effusion after intramyocardial VEGF adenovirus injections. 21 However, no significant adverse events have been reported in clinical intramyocardial VEGF gene therapy trials. 1, 8, 19 In conclusion, results of our safety study suggest that the catheter-mediated intracoronary VEGF-A gene transfer is safe and does not increase the risk of MACE, arrhythmias, cancer, diabetes or other diseases during the long-term follow-up.
Materials and methods

Patient selection
The KAT was carried out in cardiology centres at Kuopio and Helsinki University Hospitals. The trial has been approved by the local ethics committees, the Finnish Board for Gene Technology and the Finnish Agency for Medicinal Products. Informed consent was obtained from all patients. The patients also gave their informed consent for the long-term follow-up questionnaire. They were treated in a double-blind manner and were assigned randomly to three study groups. Detailed inclusion and exclusion criteria have been described. 2 In brief, the patients were 38-75 years of age and had stable CCS 2-3 angina pectoris, and a hemodynamically significant stenosis in the main coronary artery suitable for angioplasty and stenting. Patients with diffuse CAD, or history of diabetes or malignancy were excluded.
Vectors and gene transfer
Clinical grade E1-, partial E3-deleted, first-generation serotype 5 adenoviruses were used in this study. 4, 9 Adenoviruses containing a CMV-hVEGF 165 expression cassette were produced under good clinical practice GMP in 293 cells, as described. 4 They were analyzed for the absence of replication-competent viruses by means of a cytopathic effect assay on A549 cells, and viral preparations were examined to be free of any microbiological or endotoxin contamination (o20 EU/dose, Whittaker).
9,12 DOTMA:DOPE (1:1) liposomes (Valentis Inc., Burlingame, CA, USA). A volume of 2000 ml (1 mg ml À1 ) of plasmid was diluted with 1000 ml of Ringer's solution. Plasmids used for this study were manufactured under GMP, and were analyzed to be Long-term safety of VEGF gene therapy M Hedman et al free of any microbiological or endotoxin contamination (o200 EU per dose) as described. 2, 4 Percutaneous coronary intervention was carried out according to standard clinical practice, using the femoral approach. Stenting was used in 92 (90%) patients. Coronary artery gene transfer was carried out at the site of PCI immediately after the angioplasty and before stenting, using an infusion-perfusion catheter (Dispatch, Boston Scientific, Natic, MA, USA). Details of the gene transfer procedure have been reported. 2 Thirty-seven patients received VEGF-adenovirus, 28 patients received VEGF-plasmid/liposome and 38 control patients received Ringer's lactate.
Long-term follow-up
For the long-term follow-up, the patients were interviewed by telephone on the basis of a standardized questionnaire focusing on their current status of health, working ability, exercise tolerance, recurrence of coronary symptoms, incidence of acute coronary and cerebrovascular events and need for new coronary interventions, incidence of arrhythmias and need for cardiac pacemakers. Moreover, incidence of other diseases, such as cancer and diabetes or diabetic complications, as well as their personal experience of the treatment was recorded. Patients, who could not be reached by telephone, were sent a questionnaire exploring the same issues as in the telephone interview. Patients who had died (n ¼ 8) during the follow-up were explored from the Finnish Population Register Centre, and the causes of death were obtained from the archives of local hospitals and health centres according to the ICD-10 (International Classification of Diseases) codes. Follow-up results were obtained from 97 patients (91%).
Statistical analysis
Differences between the treatment groups were analyzed using ANOVA (analysis of variance) and Bonferroni's modified t-test for continuous variables, and using Chi-squared test for dichotomous variables (SPSS 14.0 program, SPSS Inc, Chicago, IL, USA). Overall, 95% confidence intervals were used for comparisons of incidences. Results were considered statistically significant at a value of Po0.05.
